|
Indication & Dosage |
|
|
Oral |
RELIEF OF MODERATE TO SEVERE PAIN |
Adult:
As hydrochloride: 50-100 mg every 3-4 hrs; max 600 mg daily. Take after food. |
|
Oral |
RELIEF OF MODERATE TO SEVERE PAIN |
Child:
6-12 yr: As hydrochloride: 25 mg every 3-4 hr. |
|
Parenteral |
RELIEF OF MODERATE TO SEVERE PAIN |
Adult:
30-60 mg SC, IM or IV Inj given every 3-4 hr. |
|
Parenteral |
RELIEF OF MODERATE TO SEVERE PAIN |
Child:
>1 yr: up to 1 mg/kg SC, IM; up to 500 mcg/kg IV every 3-4 hr. |
|
Rectal |
RELIEF OF MODERATE TO SEVERE PAIN |
Adult:
50 mg supp up to 4 times daily. |
|
Rectal |
RELIEF OF MODERATE TO SEVERE PAIN |
Child:
Not recommended. |
|
|
|
Administration |
Should be taken with food. (Take after meals.) |
|
|
Precautions |
May precipitate withdrawal in narcotic addicts; impaired respiratory, renal and hepatic function; elderly or debilitated patients; seizure-prone patients; children and infants (safety and efficacy not established in <1 yr); lactation, may impair ability to drive or operate machinery; administer IM rather than SC (when frequent injections are needed) and inj sites should be varied; morbidly obese patients; thyroid dysfunction; prostatic hyperplasia or urinary stricture; biliary tract impairment; adrenal insufficiency (including Addison's disease); abdominal conditions. |
|
|
Potentially Life-threatening
Adverse Drug Reactions |
Physical dependence; sedation, dizziness, euphoria, lightheadedness, alterations of mood; respiratory depression; visual hallucinations, disorientation, confusion; hypertension, tachycardia, circulatory depression; shock; hypotension; nausea, vomiting, constipation; seizures, diaphoresis; rash; blood dyscrasias; local tissue damages (SC), muscle fibrosis (IM). |
|
|
Adverse Drug Reactions |
Respiratory depression, hypotension, circulatory failure, deepening coma, convulsions. |
|
|
Interactions |
Depressant affects potentiated by alcohols, CNS depressants; concurrent use with fluoxetine may lead to diaphoresis, flushing and tremor associated with serotonin syndrome. |
|
|
|
|